Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults

Journal of Endocrinological Investigation

Volumn 31, Issue 9, 2008, Pages 820-838

  Giustina, A ^a,l   Barkan, A ^b   Chanson, P ^c   Grossman, A ^d   Hoffman, A ^e   Ghigo, E ^f   Casanueva, F ^g   Colao, A ^h   Lamberts, S ⁱ   Sheppard, M ^j   Melmed, S ^k  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c BICÊTRE HOSPITAL   (France)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l Montichiari Hospital   (Italy)

more..

Author keywords

Acromegaly; Growth hormone deficiency; Growth hormone replacement; Somatostatin analogs; Treatment recommendations

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTHRALGIA; BONE REMODELING; CANCER INCIDENCE; CANCER MORTALITY; CARDIOTOXICITY; CARDIOVASCULAR MALFORMATION; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GYNECOMASTIA; HORMONE RELEASE; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; IMPAIRED GLUCOSE TOLERANCE; JOINT STIFFNESS; LONG TERM CARE; METABOLIC DISORDER; MONOTHERAPY; MYALGIA; NONHUMAN; PARESTHESIA; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PREOPERATIVE CARE; QUALITY OF LIFE; RADIOSURGERY; RESPIRATORY FAILURE; RETINOPATHY; REVIEW; SIDE EFFECT; SKELETON MALFORMATION; SURGICAL RISK; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 57349198830     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349263     Document Type: Review

References (173)

1. Clemmons DR, Chihara K, Freda PU, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003, 88: 4759-67.
2. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
3. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2: 29-41.
4. AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004, 10: 213-25.
5. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998, 19: 717-97.
6. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992, 21: 597-614.
7. Molitch M, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006, 91: 1621-34.
8. Regal M, Páramo C, Sierra SM, Garcia-Mayor RV. Prevalence and indicence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001, 55: 735-40.
9. American Association of Clinical Endocrinologists Growth Hormone Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update. Endocr Pract 2003, 9: 64-76.
10. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
11. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 2003, 6: 175-80.
12. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87: 3537-42.
13. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998, 83: 3808-16.
14. Ronchi CL, Varca V, Giavoli C, et al. Long-term evaluation of post-operative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 2005, 90: 1377-82.
15. Mukherjee A, Monson JP, Jönsson PJ, Trainer PJ, Shalet SM; KIMS International Board. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab 2003, 88: 5865-70.
16. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1,-2, and -3. J Clin Endocrinol Metab 2001, 86: 1091-8.
17. Barreca A, Ciccarelli E, Minuto F, Bruzzi P, Giordano G, Camanni F. Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh) 1989, 120: 629-35.
18. Barreca A, Ponzani P, Arvigo M, Giordano G, Minuto F. Effect of the acid-labile subunit on the binding of insulin like growth factor (IGF)binding protein-3 to [1251]IGF-I. J Clin Endocrinol Metab 1995, 80: 1318-24.
19. Ferone D, Resmini E, Bocca L, Giusti M, Barreca A, Minuto F. Current diagnostic guidelines for biochemical diagnosis of acromegaly. Minerva Endocrinol 2004, 29: 207-23.
20. Minuto F, Resmini E, Boschetti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute post glucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 2004, 61: 138-44.
21. Freda PU. Pitfalls in the biochemical assessment of acromegaly. Pituitary 2003, 6: 135-40.
22. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol 2005, 153: 195-201.
23. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96: 7324-9.
24. Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 2005, 90: 2117-21.
25. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004, 102: 61-85.
26. Giustina A, Casanueva FF, Cavagnini F, et al; The Pituitary Society and the European Neuroendocrine Association. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003, 26: 1242-7.
27. Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004, 89: 5308-13.
28. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004, 151: 309-15.
29. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005, 20: 1837-44.
30. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005, 90: 2731-9.
31. Jenkins PJ, Sohaib SA, Akker S, et al. The pathology of median neuropathy in acromegaly. Ann Intern Med 2000, 133: 197-201.
32. Kauppinen-Mäkelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081-6.
33. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293-9.
34. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74.
35. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 86-91.
36. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after trans-sphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
37. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004, 89: 2789-96.
38. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in parents with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.
39. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152: 379-87.
40. Fahlbusch R, Keller B, Ganslandt O, Kreutzer J, Nimsky C. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol 2005, 153: 239-48.
41. De P, Rees DA, Davies N, et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria for remission. J Clin Endocrinol Metab 2003, 88: 3367-72.
42. Freda PU, Wardlaw SL, Post K. Long-term endocrinological follow-up evaluation in 115 patients who under went transsphenoidal surgery for acromegaly. J Neurosurg 1998, 89: 353-8.
43. Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res 2000, 53: 71-5.
44. Kreutzer J, Vance M, Lopes MB, Laws ER. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001, 86: 4072-7.
45. Kaltsas GA, Isidori AM, Florakis D, et al. Predictors of outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001, 86: 1645-52.
46. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006, 91: 85-92.
47. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. QJM 1999, 92: 741-5.
48. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999, 50: 561-7.
49. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997, 40: 225-36.
50. Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow up of 98 patients. Neurosurgery 2001, 48: 1239-43.
51. Hakala P, Randell T, Valli H. Laryngoscopy and fibreoptic intubation in acromegalic patients. Br J Anaesth 1998, 80: 345-7.
52. Seidman PA, Kofke WA, Policare R, Young M. Anaesthetic complications of acromegaly. Br J Anaesth 2000, 84: 179-82.
53. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002, 87: 99-104.
54. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005, 63: 168-75.
55. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001, 86: 140-5.
56. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100: 2386-92.
57. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab 2001, 86: 2161-9.
58. Ferone D, Saveanu A, Culler MD, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007, 156: 23-8.
59. Culler MD. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis 2004, 36: S17-25.
60. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 2000, 288: 154-7.
61. Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003, 88: 5414-21.
62. Svensson J, Bengtsson B-A, Rosén T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004, 89: 3306-12.
63. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005, 153: 135-41.
64. Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005, 28: 21-7.
65. Melmed S, Casanueva FF, Cavagnini F, et al; Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054-8.
66. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrionol Metab 1998, 83: 2646-52.
67. Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988, 68: 854-67.
68. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998, 83: 3411-8.
69. Ayuk J, Bates AS, Holden N, Clayton RN, Sheppard MC, Stewart PM. A prospective study of an initial cohort of 274 acromegalic patients drawn from a single health authority district in the United Kingdom. Proceedings of the 11th International Congress of Endocrinology, Sydney, 2000.
70. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.J Clin Endocrinol Metab 1998, 83: 2730-4.
71. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41: 95-102.
72. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980, 12: 71-9.
73. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 1995, 43: 517-22.
74. Wright AD, Hill DM, Lowry C, Fraser RT. Mortality in acromegaly. Q J Med 1970, 39: 1-16.
75. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002, 87: 4554-63.
76. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000, 53: 577-86.
77. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86: 2779-86.
78. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999, 141: 267-71.
79. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998, 48: 311-6.
80. Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endoerinol Metab 1997, 82: 23-8.
81. KendalI-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000, 3: 61-5.
82. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999, 1: 105-14.
83. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996, 45: 67-71.
84. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995, 80: 3267-72.
85. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999, 51: 275-80.
86. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3034-40.
87. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465-73.
88. Sheppard ME. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 387-99.
89. Ayuk J, Stewart SE, Stewart PM, Sheppard MC; European Sandostatin LAR Group. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004, 60: 375-81.
90. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004, 151: 317-24.
91. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405-10.
92. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856-63.
93. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreatide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002, 56: 65-71.
94. Herman-Bonert VS, Lib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000, 85: 2958-61.
95. Schreiber I, Buchfelder M, Droste M, et al; the German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007, 156: 75-82.
96. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005, 90: 5684-91.
97. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467-77.
98. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002, 87: 1797-804.
99. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002, 12: 418-24.
100. Abe T, Lüdecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001, 145: 137-45.
101. Barkan AL, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995 shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988, 67: 1040-8.
102. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997, 82: 3308-14.
103. Lucas-Morante T, García-Uría J, Estrada J, et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 1994, 81: 10-4.
104. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996, 45 (Suppl 1): 72-4.
105. Tachibana E, Saito K, Yoshida J. Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol Med Chir (Tokyo) 1999, 39: 496-9.
106. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999, 84: 3551-5.
107. Fahlbusch R, Honegger J, Buchfelder M. Acromegaly - the place of the neurosurgeon. Metabolism 1996, 45 (SuppI 1): 65-6.
108. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 1999, 141: 399-405.
109. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171-7.
110. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-9.
111. van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during co treatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001,86: 478-81.
112. Drake WM, Berney DM, Kovacs K, Monson JP. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur J Endocrinol 2005, 153: 203-5.
113. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013-8.
114. Attanasio R, Baldelli R, Pivanello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003, 88: 5258-65.
115. Cozzi R, Attanasio R, Grottoli S, et al. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? J Endocrinol Invest 2004, 27: 1040-7.
116. Bonadonna S, Manelli F, Burattin A, Villa S, Agabiti Rosei E, Giustina A. Shortening the intervals between octreotide LAR 30 mg intramuscular injections from 28 to 21 days may improve GH control in patients with active acromegaly. J Endocrinol Invest 2003, 26.
117. Ballarè E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001, 86: 3809-14.
118. Tulipano G, Bonfanti C, Milani G, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone secreting adenoma cells in vitro. Neuroendocrinology 2001, 73: 344-51.
119. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737-40.
120. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006, 29: 86-93.
121. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005, 152: 61-6.
122. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004, 61: 209-15.
123. Marzullo P, Ferone D, Di Somma C, et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999, 1: 115-20.
124. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007, 356: 6-9.
125. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005, 90: 5627-31.
126. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365: 1644-6.
127. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006, 91: 1239-45.
128. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003, 88: 3105-12.
129. Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams textbook of endocrinology. 10th ed. Philadelphia: Saunders. 2003, 1003-114.
130. Shalet SM. Growth hormone outgrows growth. Clin Endocrinol (Oxf) 2004, 61: 1-9.
131. Marzullo P, Di Somma C, Pratt KL, et al. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001, 86: 3001-8.
132. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ; HyposCCS Advisory Board; U.S. HypoCCS Study Group. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002, 87: 477-85.
133. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996, 134: 352-6.
134. Consensus guidelines of the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998, 83: 379-81.
135. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML; T002 Study Group. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 2004, 89: 3224-33.
136. Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? Clin Endocrinol (Oxf) 1995, 43: 143-9.
137. Kehely A, Bates PC, Frewer P, et al. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 2002, 87: 1974-9.
138. Radetti G, Gentili L, Lepidi M. Comment on growth hormone therapy and retinal changes mimicking diabetic retinopathy. J Clin Endocrinol Metab 2000, 85: 923.
139. Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 1993, 39: 417-25.
140. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005, 90: 800-4.
141. Agha A, Walker D, Perry L, et al. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) 2007, 66: 72-7.
142. Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab 2002, 87: 2042-5.
143. Giavoli C, Libé R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 2004, 89: 5397-401.
144. Rodríguez-Arnao J, Perry L, Besser GM, Ross RJ. Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 1996, 45: 33-7.
145. Bates AS, Bullivant B, Sheppard MC, Stewart PM. Life expectancy following surgery for pituitary tumours. Clin Endocrinol (Oxf) 1999, 50: 315-9.
146. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996, 81: 1169-72.
147. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46: 75-81.
148. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336: 285-8.
149. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001, 357: 425-31.
150. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4: 505-18.
151. Water MJ, Conway-Campbell BL. The oncogenic potential of autocrine human growth hormone in breast cancer. Proc Natl Acad Sci U S A 2004, 101: 14992-3.
152. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001, 86: 2935-41.
153. Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001, 86: 2929-34.
154. Renehan AG, Zwahlen M, Minder C, O'Dwyer SL, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein 3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363: 1346-53.
155. Le Roux CW, Jenkins PJ, Chew SL, et al. Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. Eur J Endocrinol 2002, 147: 59-63.
156. Janssen JA, Wildhagen MF, Ito K, et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 2004, 89: 4391-6.
157. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002, 360: 273-7.
158. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M, Giustina A. GH deficiency in the adult and bone. J Endocrinol Invest 2005, 28 (SuppI): 18-23.
159. Corpas E, Harman SM, Blackman MR. Human growth hormone and aging. Endocr Rev 1993, 14: 20-39.
160. Doga M, Bonadonna S, Gola M, et al. Current guidelines for adult GH replacement. Rev Endocr Metab Disord 2005, 6: 63-70.
161. Wüster C, Abs R, Bengtsson BA, et al. KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001, 16: 398-405.
162. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 2004, 89: 1124-30.
163. Davidson P, Milne R, Chase D, Cooper C. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2004, 60: 92-8.
164. Lunt M, Felsenberg D, Reeve J, et al. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 1997, 12: 1883-94.
165. Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 2005, 20: 1778-84.
166. Wüster C. Fracture rates in patients with growth hormone deficiency. Horm Res 2000, 54: 31-5.
167. Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 2006, 21: 520-8.
168. Hoffman AR. Treatment of the adult growth hormone deficiency syndrome: directions for future research. Growth Horm IGF Res 2005, 15 (Suppl A): 48-52.
169. Radcliffe DJ, Pliskin JS, Silvers JB, Cuttler L. Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics 2004, 22: 499-524.
170. Bryant J, Loveman E, Chase D, et al. Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation. Health Technol Assess 2002, 6: 1-106.
171. Deijen JB, Arwert LI, Witlox J, Drent ML. Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis. Health Qual Life Outcomes 2005, 3: 63.
172. Hernberg-Ståhl E, Luger A, Abs R, et al; KIMS International Board; KIMS Study Group. Pharmacia International Metabolic Database. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 2001, 86: 5277-81.
173. Dixon S, McEwan P, Lacey L. Preliminary cost-effectiveness model of treatment with Genotropin in adults with growth hormone deficiency in the United Kingdom. Paper presented at the 84th Annual Endocrine Society Meeting; 2002 Jun 19-22; San Francisco (CA).